Y-Mabs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Y-Mabs Therapeutics reports record revenues and strategic growth initiatives

Y-Mabs Therapeutics demonstrated strong financial performance in Q4 2022, with record revenues and effective cost management.
The company's focus on product development and market expansion, coupled with strategic restructuring, positions it for sustainable growth.
While facing financial challenges and competitive pressures, Y-Mabs Therapeutics has opportunities for portfolio expansion and market penetration.

Y-Mabs Therapeutics Inc achieves record revenue, eyes international expansion

Y-Mabs Therapeutics Inc reported strong performance in Q1 2023, driven by record net product revenue and positive sales trends for DANYELZA.
The company's focus on R&D, commercialization efforts, and strategic partnerships positions it well for future growth and market expansion.
While facing challenges such as market competition and restructuring, Y-Mabs Therapeutics Inc has opportunities to capitalize on its innovative technologies and market presence.
With updated financial guidance and a clear roadmap for product development, the company is poised for continued success and revenue growth in 2023.

Y-Mabs reports robust Q2 earnings, eyes international expansion and label growth

Y-Mabs Therapeutics Inc demonstrated strong financial performance with notable revenue growth for DANYELZA and advancements in their SADA platform.
While facing challenges in competitive dynamics and treatment optimization, the company is strategically positioned for international market expansion and revenue diversification.
Opportunities lie in market penetration strategies, upcoming label expansions, and continued product development efforts, indicating a positive outlook for future growth and innovation.

Y-Mabs Therapeutics reports strong Q3 performance and eyes oncology expansion

Y-Mabs Therapeutics showcased robust financial performance, strong commercial traction for DANYELZA, and promising advancements in the SADA platform.
While facing challenges in scalability and dose optimization, the company's strategic strengths lie in leadership changes, clinical progress, and market penetration.
Opportunities for growth include expanding indications, optimizing treatment protocols, and enhancing visibility through data presentations and partnerships.

Y-mAbs reports strong Q4 earnings, eyes global expansion and program innovations

Y-mAbs Therapeutics showcased robust financial performance in Q4 2023, driven by strong DANYELZA net product sales and revenue growth.
Effective cost management, expansion plans into key markets, and enhanced marketing efforts position the company for continued success.
While facing challenges in managing expenses and addressing analyst inquiries, Y-mAbs has opportunities for growth through international expansion and program innovations.

Y-mAbs reports record DANYELZA sales, eyes global expansion and innovation

Y-mAbs Therapeutics showcased robust financial performance with record DANYELZA sales, underpinned by strategic expansion efforts and progress in clinical programs.
While facing questions on growth strategies and potential seasonality challenges, the company's strong balance sheet and focus on innovation position it well for future success.
By emphasizing responsible capital allocation, global expansion, and advancements in cancer treatment options, Y-mAbs is poised to navigate challenges and seize opportunities for sustained growth.

Y-mAbs Therapeutics reports revenue growth and promising clinical outcomes

Y-mAbs Therapeutics Inc. delivered solid financial performance, strong product sales, and promising clinical trial outcomes in Q2 2024, positioning the company for continued growth.
While facing challenges in managing cash burn and sustaining revenue growth, the company's commitment to innovation and patient care presents opportunities for future success.
With a revised revenue guidance and focus on advancing novel therapies, Y-mAbs Therapeutics Inc. remains dedicated to improving patient lives and driving growth in the biopharmaceutical sector.

Y-Mabs Therapeutics reports mixed Q3 performance with growth opportunities

Y-Mabs Therapeutics faced challenges with declining DANYELZA revenues outside the U.S.
However, the company demonstrated strengths in securing long-term exclusivity and expanding market reach.
Opportunities lie in leveraging partnerships, exploring new targets, and ongoing clinical trials.
Maintaining financial stability and meeting full-year guidance are key priorities for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Nov.  01, 2019  (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 5,134,750 shares of its common stock, at a public offering price of $28.00 per share, which includes the exercise in full of the underwriters' option to purchase 669,750 additional shares of common stock. The aggregate gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $143.8 million.  All of the shares of common stock were offered by the Company. Y-mAbs’ common stock is listed on The Nasdaq Global Select Market under the ticker symbol "YMAB."

Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB), a thinly traded small-cap oncology-focused biopharma company, said in a Friday SEC filing that its omburtamab pre-BLA meeting with the FDA may now be delayed.

Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing Timeline

NEW YORK, Oct.  28, 2019  (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of central nervous system (CNS) leptomeningeal metastases from neuroblastoma and a number of additional cancer indications. Data was presented at the International Society of Pediatric Oncology (SIOP) Annual Congress in Lyon, France on October 26, 2019 by Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (MSK) in New York.

Y-mAbs Announces Positive Omburtamab Clinical Data

NEW YORK, Oct.  25, 2019  (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on one of the Company’s lead products, naxitamab for the treatment of neuroblastoma and osteosarcoma, was made at the International Society of Pediatric Oncology (SIOP) Annual Congress held in Lyon, France. Naxitamab is currently being evaluated for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma, osteosarcoma and other GD2-positive tumors. An oral presentation was made by Dr. Shakeel Modak, and a total of five (5) poster presentations were made by Dr. Brian H. Kushner and Dr. Filemon Dela Cruz, all from Memorial Sloan Kettering (MSK) in New York.

Y-mAbs Announces Naxitamab Update

Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansions and earlier-stage pipeline efforts, according to Wedbush.

Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

NEW YORK, Aug.  30, 2019  (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of abstracts for a poster presentation and an oral presentation at the 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting held November 13 through November 16, 2019 in Tokyo, Japan.

Y-mAbs Announces Data to be Presented at 2019 CTOS

Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q2 2019 Results - Earnings Call Transcript

Shares have risen by over 25% since IPO pricing in September of last year.

Y-mAbs Therapeutics: Impressive Data In Multiple Oncology Indications, Regulatory Submissions Loom

News for Y-Mabs Therapeutics Inc Stock (YMAB)